Guardant Health Inc.
Guardant Health Amends CEO Compensation Agreements
Summary
On March 18, 2024, Guardant Health, Inc. announced that its Board of Directors approved amendments to the Letter Agreements with its co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024. The amendments maintain the annual base salary at $1 and introduce new annual RSU and PSU awards, with long-term awards tied to company performance metrics. Additionally, the filing includes financial statements and exhibits, such as the form of the Letter Agreement, as part of the 9.01 item.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement